

Education ▪ Evidence ▪ Experience

ELEVATE

ADVANCING SCIENCE IN HR+/HER2- mBC

**From clinical trial
to clinical reality**

**VIRTUAL MEETING
13–14 November 2020**

DAY 1, SESSION 1 (06:00–07:30 PST; 15:00–16:30 CET)

Management of metastatic breast cancer (mBC): Considering the evidence (90 minutes)

Chaired by Veronique Diéras

TIMING	SESSION TITLE	PRESENTER
5 minutes	Welcome and introduction	Veronique Diéras
10 minutes	Welcome from Pfizer	Chris Boshoff
15 minutes	Novel challenges for mBC treatment: Considerations with COVID-19	Veronique Diéras
15 minutes	Raising standards in HR+/HER2- mBC: Measuring recent progress	Hope S. Rugo
5 minutes	Break	
15 minutes	Adhering to best practice: Examining the latest guidelines	Giuseppe Curigliano
20 minutes	Expert discussion and Q&A	Giuseppe Curigliano, Hope S. Rugo, facilitated by Veronique Diéras
5 minutes	Summary and close	Veronique Diéras

DAY 1, SESSION 2 (08:00–09:30 PST; 17:00–18:30 CET)

Optimising mBC management in practice (90 minutes)

Chaired by Hope S. Rugo

TIMING	SESSION TITLE	PRESENTER
5 minutes	Welcome and introduction	Hope S. Rugo
15 minutes	Establishing the right care at the right time: Considerations for treatment choice	Shaheenah Dawood
15 minutes	Empowering patients: The importance of shared decision-making	Ahmad Awada
15 minutes	Genetic testing: Practical considerations and supporting next steps with the patient	Angela George
10 minutes	Expert discussion and Q&A	Ahmad Awada, Shaheenah Dawood and Angela George, facilitated by Hope S. Rugo
5 minutes	Break	
20 minutes	Managing HR+/HER2- mBC: Insights from clinical practice	Eva Ciruelos
5 minutes	Summary and close	Hope S. Rugo

DAY 2, SESSION 1 (06:00–07:30 PST; 15:00–16:30 CET)

Expanding the evidence base with real-world data (RWD) and real-world evidence (RWE) (90 minutes)

Chaired by Veronique Diéras

TIMING	SESSION TITLE	PRESENTER
5 minutes	Welcome and introduction	Veronique Diéras
15 minutes	Looking beyond clinical trials: Maximising treatment benefit in the real world	Winson Cheung
15 minutes	Real-world data, evidence, and application: Navigating RWE in clinical practice	Paul Cottu
15 minutes	Expert discussion and Q&A	Winson Cheung and Paul Cottu, facilitated by Veronique Diéras
5 minutes	Break	
20 minutes	Consensus or what more is needed? RWE in today's clinical treatment paradigm	For: Paul Cottu; Against: Javier Cortes; Moderator: Hope S. Rugo
10 minutes	Expert discussion and Q&A	Javier Cortes, Winson Cheung and Paul Cottu, facilitated by Veronique Diéras
5 minutes	Summary and close	Veronique Diéras

DAY 2, SESSION 2 (08:00–09:30 PST; 17:00–18:30 CET)

Focus on the patients (90 minutes)

Chaired by Hope S. Rugo

TIMING	SESSION TITLE	PRESENTER
5 minutes	Welcome and introduction	Hope S. Rugo
15 minutes	Looking through the eyes of a patient	Eva Schumacher-Wulf
15 minutes	Understanding the patient: Exploring the psychology of a breast cancer patient	Luzia Travado
10 minutes	Expert discussion and Q&A	Eva Schumacher-Wulf and Luzia Travado, facilitated by Hope S. Rugo
5 minutes	Break	
20 minutes	Understanding the language of breast cancer	Simon Moore
10 minutes	A new decade: Harnessing the power of hope in mBC	Ben Corn
10 minutes	Summary and meeting close	Veronique Diéras and Hope S. Rugo



This meeting is organised and funded by Pfizer.
© 2020 Pfizer Pharma GmbH. All rights reserved
Date of preparation: June 2020. PP-IBR-GLB-0264
www.pfizer.com